Agilent Shares Dip 0.36% on 33.96% Volume Rise Ranks 367th as EU Certification Elevates Oncology Diagnostic Edge

Agilent Technologies (A) closed on September 2, 2025, with a 0.36% decline in share price. The stock recorded a trading volume of $0.30 billion, a 33.96% increase from the prior day, ranking it 367th in terms of trading activity among listed stocks. The company announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic certification under EU in vitro diagnostic regulation (IVDR). This approval enables the test to identify mismatch repair (MMR) deficient colorectal cancer patients eligible for treatment with Bristol-Myers Squibb’s OPDIVO® and YERVOY® combination therapy. The panel is the first and only IVDR-approved immunohistochemical diagnostic tool for this indication in Europe.

Agilent’s MMR IHC Panel is designed to detect dysfunction in four key MMR proteins, which are linked to increased tumor mutagenesis and immunotherapy responsiveness. The certification underscores the company’s role in advancing companion diagnostics for precision oncology. The development was conducted in collaboration with Bristol-Myers Squibb, highlighting Agilent’s strategic partnerships in expanding its diagnostic portfolio. Analysts noted that the regulatory milestone could enhance the company’s market position in oncology diagnostics, though immediate stock performance remains mixed amid broader market dynamics.